|
VIMOVO™ is being developed for the relief of the signs and symptoms associated with conditions such as osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients who are at risk for developing NSAID-associated gastric ulcers. In the wake of cardiovascular safety concerns regarding the COX-2 selective NSAIDs, many physicians are now recommending traditional non-selective NSAIDs with gastroprotective co-therapy using acid-suppressive agents to prevent gastrointestinal complications. POZEN's VIMOVO™ is designed to ensure adherence since the PPI is administered with every dose of NSAID.
More Info about Vimovo
| Drug Type: | Other |
| Current FDA Status: | Approved |
| Current Drug Phase: | NDA |
|